Last reviewed · How we verify

NCT03205514: SHERLOCK

Multimodality Investigation of Intermediate Culprit Lesion With Negative FFR in NSTE-ACS

Completed Last updated 29 April 2021
What this trial tests

trial testing NSTE-ACS with intermediate stenosis and negative FFR in Myocardial Ischemia in 35 participants. Completed in 28 April 2021.

Timeline
28 June 2017
Primary endpoint
5 June 2018
28 April 2021

Quick facts

Lead sponsorUniversity Hospital of Ferrara
StatusCompleted
Study typeOBSERVATIONAL
Enrollment35
Start date28 June 2017
Primary completion5 June 2018
Estimated completion28 April 2021
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital of Ferrara

Who can join

18 and older, any sex, with Myocardial Ischemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Ten-fifteen percent of acute coronary syndromes without ST-segment elevation (NSTE-ACS) are caused by intermediate lesions without signs of unstable plaque. In this subset of patients, fractional flow reserve (FFR) has some drawbacks and may not be always able to predict outcome, especially when negative (above 0.80). In this particular nique of patients, advanced imaging techniques are suggested by International guidelines. However, it is actually unknown how these techniques may impact treatment strategies. With the present study, the investigators want to characterize the mechanism of disease in this particular subset of patients through multimodality imaging (intravascular ultrasound-near infrared spectroscopy (IVUS-NIRS), optical coherence tomography (OCT)) in order to understand the proper treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Myocardial Ischemia

Currently open trials in the same condition.

Other University Hospital of Ferrara trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03205514.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing